Industries de la santé
23 Juillet 2012
HAIFA, ISRAEL, July 18, 2012 -- Pluristem Therapeutics, Inc. (NASDAQ:PSTI; TASE: PLTR), today announced that in anticipation of initiating a Phase II study using PLX-PAD cells for the treatment of Intermittent Claudication (IC), the company has recently entered into a collaborative agreement with CPC Clinical Research (CPC) for services related to enrolling and sustaining clinical sites... |